AbbVie said it entered into an underwriting agreement with the underwriters on February 18, 2025 to issue and sell senior notes due 2028 at $1,250,000,000, due 2030 at $1,000,000,000, due 2035 at $1,000,000,000, and due 2055 at $750,000,000.

1. 01

   AbbVie said it entered into an underwriting agreement with the underwriters on February 18, 2025 to issue and sell senior notes due 2028 at $1,250,000,000, due 2030 at $1,000,000,000, due 2035 at $1,000,000,000, and due 2055 at $750,000,000.

2. 02

   The company said it is offering the senior notes due 2028 at 4.650%, due 2030 at 4.875%, due 2035 at 5.2000%, and due 2055 at 5.600%, priced at 99.867%, 99.908%, 99.857% and 99.750% of principal amount, respectively.

3. 03

   The company said net proceeds from the sale, after deducting underwriting discounts and before estimated offering expenses, are expected to be about $3.98 billion. It said the sale is expected to close on February 26, 2025, subject to customary closing conditions.

4. 04

   The company said it plans to use the net proceeds, together with cash on hand, to repurchase, redeem, satisfy and discharge, defease, make a tender offer for, or otherwise repay at maturity its 3.600% senior notes due 2025 ($3.750 billion), its 3.800% senior notes ($2.890 billion), and the 3.800% senior notes of Allergan Funding SCS ($130.225 million), and to pay any premium and accrued and unpaid interest, and/or for general corporate purposes.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.